What is RNXT's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 0.06B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for RNXT?

P/E (TTM) is n/a and 52-week range is $0.70 to $2.59 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s RNXT figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for RNXT?

The company profile lists revenue (TTM) near $2M, net income (TTM) near $-1.17B, EPS (TTM) near $-0.31 when available from the market-data feed. Figures are informational and may lag live markets.

Where is RenovoRx Inc based, and what identifiers does Chartloom list?

The company context section lists headquarters in Mountain View, California, US, 45M shares outstanding, ISIN US75989R1077 when available from company profile and filing metadata.

Please enable JavaScript to continue using this application.

RenovoRx Inc

$RNXT

Health Care · Biotechnology

IR Run Scenarios

$1.28

-3.76%

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

RenovoRx, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of a therapy platform to deliver chemotherapy. The company is headquartered in Mountain View, California and currently employs 17 full-time employees. The company went IPO on 2021-08-17. Its lead product RenovoCath a local drug delivery device, targeting high unmet medical needs. RenovoRx’s patented Trans-Arterial Micro-Perfusion (TAMP) therapy platform is designed to ensure targeted therapeutic delivery across the arterial wall near the tumor site to bathe the target tumor. RenovoRx’s novel approach to targeted treatment offers the potential for increased safety, tolerance, and improved efficacy, and to transform the lives of cancer patients by providing innovative solutions to enable targeted delivery of diagnostic and therapeutic agents. In addition to the RenovoCath device, RenovoRx is also evaluating the novel Phase III drug-device combination oncology product candidate (intra-arterial gemcitabine, known as IAG). The combination of intra-arterial infusion of chemotherapy, gemcitabine, and the RenovoCath device is being evaluated for the treatment of locally advanced pancreatic cancer.

Employees

Website

renovorx.com/

IPO

2021-08-17

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)

Net income (TTM)